Piracetam Obolenskoe, 30 pcs., 800 mg, film-coated tablets

Piracetam Obolenskoe, 30 pcs., 800 mg, film-coated tablets

Piracetam activates associative processes in the central nervous system, improves mood, memory and mentality in sick and healthy people. Stimulates intellectual activity and integrative activity of the brain, facilitates learning processes, improves connections between the cerebral hemispheres and synaptic conduction in the cortex, increases mental performance, stabilizes and restores impaired brain functions (memory, consciousness, speech). Piracetam normalizes the ratio of ADP and ATP (inhibits nucleotide phosphatase and activates adenylate cyclase), increases the activity of phospholipase A, stimulates bioenergetic and plastic processes in nervous tissue, and accelerates the exchange of neurotransmitters.

Piracetam increases the resistance of brain tissue to toxic influences and hypoxia, enhances the synthesis of phospholipids and nuclear RNA, enhances glycolytic processes and glucose utilization in the brain. Piracetam blocks platelet aggregation, improves microcirculation, optimizes the ability of red blood cells to pass through microvessels and the conformational properties of the red blood cell membrane, and increases regional blood flow in ischemic areas of the brain. Piracetam increases beta and alpha activity on the EEG and decreases delta activity. Reduces vestibular nystagmus. During hypoxia, intoxication, trauma, electroconvulsive effects have a neuroprotective effect.

Due to its antihypoxic effect, piracetam is effective in the complex treatment of myocardial infarction. Piracetam does not have anxiolytic or sedative effects.

Piracetam is absorbed almost completely and quickly after oral administration. Bioavailability is 100%. When 2 g of the drug is taken orally, the maximum plasma concentration is 40–60 mcg/ml after 30 minutes. Piracetam does not bind to plasma proteins. After 2–8 hours, the maximum concentration in the cerebrospinal fluid is created. Piracetam penetrates into all tissues and organs, and penetrates the placental barrier. Almost not metabolized. Selectively accumulates in the cerebral cortex, mainly in the parietal, frontal and occipital lobes, basal ganglia and cerebellum. The half-life of piracetam from plasma is 4–5 hours; from the cerebrospinal fluid is 6–8 hours. More than 95% of the drug is excreted unchanged by the kidneys after 30 hours. In patients with renal failure, the half-life is prolonged.

Piracetam obolenskoe

Manufacturer: FP OBOLENSKOYE CJSC (Russia)

tab., cover coated, 400 mg: 10, 15, 20, 30, 40, 45, 50, 60, 70, 75, 80, 90, 100, 105, 120, 135, 140, 150, 160, 180, 200, 210, 240 , 270, 300 or 360. Reg. No.: P No. 001564/01

Clinical and pharmacological group:

Nootropic drug

Release form, composition and packaging

Film-coated tablets

yellow, round, biconvex, oblong in shape with rounded ends, with a notch; On a cross section, two layers are visible.

Excipients:

polyethylene glycol 6000, croscarmellose sodium (primellose), magnesium stearate, colloidal silicon dioxide (aerosil), hydroxypropylcellulose, titanium dioxide, quinoline yellow.

10 pieces. — cellular contour packages (3) — cardboard packs. 10 pieces. — contour cell packaging (6) — cardboard packs. 10 pieces. — cellular contour packages (1) — cardboard packs. 10 pieces. — contour cell packaging (5) — cardboard packs. 10 pieces. — contour cell packaging (4) — cardboard packs. 10 pieces. — contour cell packaging (7) — cardboard packs. 10 pieces. — contour cell packaging (8) — cardboard packs. 10 pieces. — contour cell packaging (9) — cardboard packs. 10 pieces. — contour cell packaging (10) — cardboard packs. 10 pieces. — contour cell packaging (12) — cardboard packs. 15 pcs. — contour cell packaging (12) — cardboard packs. 15 pcs. — cellular contour packages (1) — cardboard packs. 15 pcs. — cellular contour packages (3) — cardboard packs. 15 pcs. — contour cell packaging (2) — cardboard packs. 15 pcs. — contour cell packaging (4) — cardboard packs. 15 pcs. — contour cell packaging (5) — cardboard packs. 15 pcs. — contour cell packaging (6) — cardboard packs. 15 pcs. — contour cell packaging (7) — cardboard packs. 15 pcs. — contour cell packaging (8) — cardboard packs. 15 pcs. — contour cell packaging (9) — cardboard packs. 15 pcs. — contour cell packaging (10) — cardboard packs. 20 pcs. — contour cell packaging (10) — cardboard packs. 20 pcs. — cellular contour packages (1) — cardboard packs. 20 pcs. — contour cell packaging (2) — cardboard packs. 20 pcs. — cellular contour packages (3) — cardboard packs. 20 pcs. — contour cell packaging (5) — cardboard packs. 20 pcs. — contour cell packaging (6) — cardboard packs. 20 pcs. — contour cell packaging (7) — cardboard packs. 20 pcs. — contour cell packaging (8) — cardboard packs. 20 pcs. — contour cell packaging (9) — cardboard packs. 20 pcs. — contour cell packaging (12) — cardboard packs. 30 pcs. — contour cell packaging (12) — cardboard packs. 30 pcs. — cellular contour packages (1) — cardboard packs. 30 pcs. — contour cell packaging (2) — cardboard packs. 30 pcs. — cellular contour packages (3) — cardboard packs. 30 pcs. — contour cell packaging (4) — cardboard packs. 30 pcs. — contour cell packaging (5) — cardboard packs. 30 pcs. — contour cell packaging (6) — cardboard packs. 30 pcs. — contour cell packaging (7) — cardboard packs. 30 pcs. — contour cell packaging (8) — cardboard packs. 30 pcs. — contour cell packaging (9) — cardboard packs. 30 pcs. — contour cell packaging (10) — cardboard packs.

Description of the active components of the drug "Piracetam"

pharmachologic effect

Nootropic drug. It has a positive effect on metabolic processes and blood circulation in the brain. Increases glucose utilization, improves metabolic processes, improves microcirculation in ischemic areas, inhibits aggregation of activated platelets. It has a protective effect against brain damage caused by hypoxia, intoxication, and electric shock. Improves integrative brain activity. Does not have a sedative or psychostimulating effect.

Indications

Memory impairment, dizziness, decreased concentration, emotional lability, dementia due to cerebrovascular accidents (ischemic stroke), brain injury, Alzheimer's disease, in old age; comatose states of vascular, traumatic or toxic origin; treatment of abstinence and psychoorganic syndrome in chronic alcoholism; learning disabilities in children not associated with inadequate training or characteristics of the family environment (as part of combination therapy); sickle cell anemia (as part of combination therapy).

Dosage regimen

Adults orally - 30-160 mg/kg/day in 2-4 doses. Duration of treatment is 6-8 weeks.

If necessary, apply intramuscularly or intravenously at an initial dose of 10 g/day. When administered intravenously to patients in severe condition, the daily dose can be 12 g. After clinical improvement, the dose is gradually reduced and switched to oral administration.

Children orally - 30-50 mg/kg/day in 2-3 doses. Treatment should be continued for at least 3 weeks.

Side effect

From the digestive system:

rarely - dyspeptic symptoms, abdominal pain.

From the side of the central nervous system:

rarely - nervousness, agitation, irritability, anxiety, sleep disorders, dizziness, headache, tremor, in some cases - weakness, drowsiness.

Other:

increased sexual activity.

Contraindications

Hemorrhagic stroke, severe renal failure (with CC<20 ml/min), hypersensitivity to piracetam.

Pregnancy and lactation

Adequate and strictly controlled studies of the safety of piracetam during pregnancy have not been conducted. Use is possible only in cases where the expected benefit to the mother outweighs the possible risk to the fetus.

Piracetam appears to pass into breast milk. If it is necessary to use it during lactation, the issue of stopping breastfeeding should be decided.

In experimental studies

In animals, no negative effects of piracetam on the fetus were detected.

Use for renal impairment

Contraindicated in severe renal failure (creatinine clearance <20 ml/min).

Use with caution in patients with renal failure. Continuous monitoring of renal function indicators is recommended.

special instructions

Use with caution in patients with severe hemostatic impairment, during major surgical operations and severe bleeding; with renal failure.

Continuous monitoring of renal function indicators is recommended.

If sleep disturbances occur, it is recommended to stop taking piracetam in the evening and add this dose to the daytime dose.

Drug interactions

A case of interaction of piracetam with simultaneous use with a thyroid extract containing triiodothyronine and tetraiodothyronine is described, when the patient experienced anxiety, irritability and sleep disorders.

When used simultaneously with thyroid hormones, the development of central effects is possible - tremor, anxiety, irritability, sleep disturbances, confusion.

With the simultaneous use of central nervous system stimulants, the psychostimulating effect may be enhanced.

When used simultaneously with antipsychotics, an increase in extrapyramidal disorders is observed.

Drug interactions

A case of interaction of piracetam with simultaneous use with a thyroid extract containing triiodothyronine and tetraiodothyronine is described, when the patient experienced anxiety, irritability and sleep disorders.

When used simultaneously with thyroid hormones, the development of central effects is possible - tremor, anxiety, irritability, sleep disturbances, confusion.

With the simultaneous use of central nervous system stimulants, the psychostimulating effect may be enhanced.

When used simultaneously with antipsychotics, an increase in extrapyramidal disorders is observed.

Piracetam Obolenskoye tablet p/o film 800mg 30 pcs

Pharmacological group:

Nootropic drug.
Pharmacodynamics:
Piracetam, a cyclic derivative of gamma-aminobutyric acid GABA, is a nootropic drug that directly affects the brain, improving cognitive processes (learning ability, memory, attention, as well as mental performance). It affects the central nervous system (CNS) in various ways: it changes the speed of propagation of excitation in the brain, improves metabolic processes in nerve cells, improves microcirculation, affecting the rheological characteristics of the blood without causing vasodilation.

Piracetam inhibits platelet aggregation and restores the elasticity of the erythrocyte membrane, reduces the adhesion of erythrocytes. At a dose of 9.6 g, it reduces the concentration of fibrinogen and von Willebrand factor by 30-40% and prolongs bleeding time. Improves communication between the cerebral hemispheres and synoptic conduction in neocortical structures. Piracetam has a protective and restorative effect in cases of impaired brain function due to hypoxia and intoxication. Reduces the severity and duration of vestibular nystagmus.

Pharmacokinetics:

When the drug is taken orally, it is quickly and almost completely absorbed, peak concentrations are reached 1 hour after administration. The bioavailability of the drug is approximately 100%. After taking a single dose of 2 g, the maximum concentration is 40-60 mcg/ml, which is achieved in the blood after 30 minutes and 5 hours in the cerebrospinal fluid after intravenous administration. The apparent volume of distribution of piracetam is about 0.6 l/kg. The half-life of the drug from blood plasma is 4-5 hours and 8.5 hours from cerebrospinal fluid, which is prolonged in case of renal failure. The pharmacokinetics of piracetam does not change in patients with liver failure.

Penetrates the blood-brain and placental barrier and membranes used in hemodialysis. In animal studies, piracetam selectively accumulates in the tissues of the cerebral cortex, mainly in the frontal, parietal and occipital lobes, cerebellum and basal ganglia. Does not bind to blood plasma proteins and is not metabolized in the body. 80-100% of piracetam is excreted unchanged by the kidneys by renal filtration. The renal clearance of piracetam in healthy volunteers is 86 ml/min.

Piracetam

Piracetam is a nootropic drug that has a positive effect on metabolic processes and blood circulation in the brain. The uniqueness of nootropics is that of all neurotropic drugs, only they can be used for both treatment and prevention. The scope of their application is very wide and extends far beyond the boundaries of any single nosology. Thus, nootropics are regulators of natural metabolic processes in the central nervous system, ensuring their unhindered flow under conditions of various stresses, as well as during aging of the body, when the brain becomes susceptible to vascular lesions, Parkinson’s disease, dementia, etc. The “pioneer” among nootropics is piracetam. Despite this, the drug is still the most popular nootropic drug, filling more than half of the total nootropic market. The biography of piracetam as a drug dates back to 1963. However, its main advantage - the ability to improve memory and assimilation of information - was discovered much later, in 1972. Piracetam has a number of important characteristics. Thus, it increases the utilization of glucose by tissues, facilitates metabolic processes, stimulates blood circulation in ischemic areas, and suppresses platelet aggregation (sticking together). Piracetam has a protective effect on the brain during various types of damage: hypoxia, toxic or electrical damage. Improves cognitive functions without having a psychostimulating or sedative effect. Among the advantages of piracetam are the lack of binding to blood plasma proteins and non-metabolism, which makes its use more predictable and significantly reduces the risk of developing unwanted side effects. Piracetam can be successfully combined with drugs from various pharmacological groups. Side effects when using piracetam are extremely rare and occur mainly in elderly patients at the initial stage of treatment, as well as when the doses recommended by the instructions are exceeded.

When taken orally, the drug is quickly and completely absorbed from the digestive tract. The maximum concentration of the active substance in the blood plasma is achieved on average after half an hour. The half-life of piracetam is 4-5 hours. The drug is excreted unchanged in the urine. In persons suffering from insufficient renal function, the half-life of piracetam increases, which must be taken into account when determining the therapeutic dose.

Piracetam is available in the form of tablets, capsules and solution for intravenous and intramuscular administration. The dose is calculated based on the patient's body weight. For adults, the daily dose is 30-160 mg per 1 kg in 2-4 doses. The duration of the medication course is 1.5-2 months. Depending on the clinical situation, piracetam can be prescribed in injection form at an initial dose of 10 g per day. When administered intravenously to patients in serious condition, the dose can be increased to 12 g. As the clinical situation improves, the dose is progressively reduced and the patient is transferred to piracetam capsules or tablets. Children are prescribed the drug in a daily dose of 30-50 mg per 1 kg of body weight in 2-3 doses. The duration of pharmacotherapy is at least 3 weeks. Patients with serious hemostasis disorders, severe bleeding, those who have undergone major surgery, and those suffering from renal failure should take piracetam with extreme caution. In case of somnological disorders, it is recommended to discontinue the evening dose of the drug and increase its daily dose proportionally. When combining piracetam with thyroid hormones, central effects may develop - anxiety, irritability, tremor, confusion. When combining the drug with stimulants of the central nervous system, the psychostimulating effect may be potentiated. The combination of piracetam with antipsychotics causes increased extrapyramidal disorders.